Allergy Therapeutics (AGY)
AGY Share PerformanceMore
|52 week high||39.50 10/10/17|
|52 week low||23.00 28/03/17|
|52 week change||0.10 (0.40%)|
|4 week volume||2,141,657 27/01/18|
Latest News« previous» nextMore
Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in London
15/02/2018 - 09:24 StockMarketWire
If you are looking for some investment ideas for your ISA, then come along the Shares and AJ Bell Investor Evening in Lo...
12/02/2018 - 08:38 StockMarketWire
Allergy Therapeutics plc announced Monday that recruitment has been completed in its grass allergy Phase II study with r...
12/02/2018 - 07:00 RNS
RNS Number: 5209E Allergy Therapeutics PLC 12 February 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 12 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specia...
02/02/2018 - 07:15 RNS
RNS Number: 7100D Allergy Therapeutics PLC 02 February 2018 Hardman Research: Growth in a tough market Growth in a tough market: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in th...
31/01/2018 - 14:54 StockMarketWire
Allergy Therapeutics said its was trading in line with its expectations, with first-half revenues to rise 4.4% to 42.2m. On con...
31/01/2018 - 07:00 RNS
RNS Number: 4048D Allergy Therapeutics PLC 31 January 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Trading Update Market share gains driving top line growth Strong cash position sustained by good performance. 31 January 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in alle...
10/01/2018 - 15:19 RNS
RNS Number: 5221B Allergy Therapeutics PLC 10 January 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy The...
09/01/2018 - 07:23 StockMarketWire
Allergy Therapeutics said recruitment of the group's phase III clinical trial with PQ Birch (PQBirch301) has been completed...
|Dividend yield||0 %|
Latest discussion posts More
“Things are looking good for AGY ,I just hope the margins are holding up , as there is no point in selling more products at reduced margins. BE HAPPY DAVE Allergy ...”▼
“Monday 29th (Tentative)”▼
“09 January 2018 Allergy Therapeutics plc PQ Birch Phase III clinical trial completes recruitment 9 January 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated ...”▼
Codes & Symbols
|Symbols||AGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment